A follow-up study of multibacillary Hansen's disease patients treated with multidrug therapy (MDT) or MDT + immunotherapy (IMT).
Multibacillary (MB) leprosy patients treated with multidrug therapy (MDT) or MDT + immunotherapy (IMT) with BCG + heat-killed Mycobacterium leprae were tested annually for their ability to proliferate in vitro to the mycobacterial antigens BCG, M. leprae soluble extract, and intact M. leprae. IgM antibody responses to phenolic glycolipid I (PGL-I) were measured, as well as serum nitrite levels in patients' sera, before, during and after treatment. Patients who received only MDT did not present cellular reactivity to intact M. leprae antigens, in contrast to the results obtained with BCG, which elicited reactivity at time zero, that increased after treatment. Regarding PGL-I antibody variations in relation to the initial value, we observed a statistically significant marked decrease at the end of 2 years which continued to fall in successive evaluations. MB patients showed high initial serum nitrite concentrations which dropped drastically with treatment. This decay was apparently associated with the bacillary load present in these patients. The group submitted to IMT + MDT showed high and long-lasting T-cell responses to mycobacterial antigens in a significant number of initially unresponsive MB patients. There was a marked increase to M. leprae soluble extract and BCG, as well as a more variable response to whole bacilli. The antibody levels in this group of patients are sustained for a somewhat longer period and decreased more slowly during the 5-year follow up.
Rada
E
E
Instituto de Biomedicina, Caracas, Venezuela.
Ulrich
M
M
Aranzazu
N
N
Rodriguez
V
V
Centeno
M
M
Gonzalez
I
I
Santaella
C
C
Rodriguez
M
M
Convit
J
J
D000907:Antibodies, Bacterial / Q000097:blood; D000942:Antigens, Bacterial; D001428:Bacterial Vaccines / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006017:Glycolipids; D006801:Humans; D007917:Leprostatic Agents / Q000627:therapeutic use*; D007918:Leprosy / Q000188:drug therapy / Q000276:immunology* / Q000628:therapy*; D008213:Lymphocyte Activation; D008297:Male; D009166:Mycobacterium leprae / Q000276:immunology*; D009573:Nitrites / Q000097:blood; D014611:Vaccination; D015164:Vaccines, Inactivated
D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D001428:Bacterial Vaccines; D006017:Glycolipids; D007917:Leprostatic Agents; D009573:Nitrites; D015164:Vaccines, Inactivated; C060596:anti-leprosy vaccine; C045169:phenolic glycolipid I, Mycobacterium leprae